At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer is in the final stages of a deal to purchase Metsera, offering $47.50 in cash per share and an additional $22.50 if specific performance targets are achieved, as reported by Financial Times.

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...